Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12161552 | 0.92 | P2RY12 (0.44) | P2RY12PPARGMAPTKDM4ECA12 | |
| SCHEMBL9922782 | 0.87 | P2RY12 (0.43) | P2RY12PPARGMAPTKDM4ECA12 | |
| SCHEMBL9923095 | 0.86 | P2RY12 (0.53) | P2RY12PPARGMAPTKDM4ELMNA | |
| SCHEMBL12161551 | 0.79 | P2RY12 (0.43) | P2RY12PPARGMAPTKDM4ECA12 | |
| SCHEMBL9922812 | 0.77 | P2RY12 (0.46) | P2RY12MAPTKDM4ECA12CA9 | |
| SCHEMBL9922311 | 0.75 | P2RY12 (0.43) | P2RY12MAPTKDM4ECA12CA9 | |
| SCHEMBL12177272 | 0.75 | P2RY12 (0.36) | P2RY12PPARGKDM4ECA12CA9 | |
| SCHEMBL9923097 | 0.74 | P2RY12 (0.52) | P2RY12PPARGMAPTKDM4ETP53 | |
| SCHEMBL17715364 | 0.73 | MAPT (0.49) | MAPTKDM4ECA12CA9CA1 | |
| SCHEMBL12161522 | 0.72 | P2RY12 (0.44) | P2RY12PPARGMAPTKDM4ECA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | P2RY12 19/4885PPARG 312/4885MAPT 4832/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | P2RY12 18/4885PPARG 301/4885MAPT 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.